How to Get Rezdiffra (Resmetirom) in Tennessee

The direct answer

Resmetirom (Rezdiffra) received FDA approval in 2024 as the first drug indicated for adults with MASH and moderate-to-advanced fibrosis (F2-F3), to be used with diet and exercise. Nothing about Tennessee law restricts who can prescribe it or how it can be dispensed: physicians, nurse practitioners, and physician assistants with Tennessee prescriptive authority can write for it, telehealth visits can establish the prescriber-patient relationship, and both specialty and 503A compounding pharmacies operate in the state under standard federal and state rules. What actually determines how fast a Tennessee patient gets the drug is fibrosis-stage confirmation (biopsy or noninvasive testing) and the specific insurance plan's prior-authorization criteria, which vary by payer and change over time. General availability is established; the timeline and out-of-pocket cost for any individual patient are not.

What resmetirom is, and what it is not

Resmetirom is a small-molecule, orally administered agonist of the thyroid hormone receptor beta (THR-beta), taken once daily. It is FDA-approved specifically for MASH with fibrosis stage F2 or F3, it is not approved for simple fatty liver without fibrosis, and it is not approved for cirrhosis (F4). It is not a weight-loss drug, an insulin sensitizer, or a GLP-1 receptor agonist, though patients with MASH frequently also have obesity or type 2 diabetes and may be on those medications concurrently. The registration trial supporting approval was a large, randomized, placebo-controlled phase 3 study (commonly referred to as MAESTRO-NASH) that reported higher rates of NASH resolution and fibrosis improvement with resmetirom than placebo, along with reductions in LDL cholesterol. Readers should treat any specific percentage figures from that trial as needing verification against the current FDA label or the published trial report before being quoted to a patient; this article intentionally does not restate exact numbers pulled from a secondary source.

Getting a prescription in Tennessee: the four practical stages

Stage 1: Confirm the diagnosis and fibrosis stage. A prescriber needs evidence of MASH with F2 or F3 fibrosis. Liver biopsy remains the reference standard, but noninvasive tools, FibroScan (vibration-controlled transient elastography) and the FIB-4 index, are widely used for staging and are accepted by many payers. Several Tennessee gastroenterology and hepatology practices offer in-office FibroScan.

Stage 2: Get the prescription written. Tennessee does not restrict resmetirom to hepatology subspecialists. In practice, most prescriptions originate from gastroenterologists or hepatologists because they typically run the diagnostic workup, but a primary care provider who has the required lab and imaging results in hand can legally prescribe it.

Stage 3: Prior authorization. Most commercial plans and pharmacy benefit managers require prior authorization before covering resmetirom, given its specialty-tier cost. Turnaround time varies by payer.

Stage 4: Pharmacy fulfillment. Most patients fill through a specialty pharmacy that coordinates prior authorization and, where eligible, manufacturer copay support. Retail pharmacies that stock the drug can also dispense it; availability is more consistent at larger chains in metro areas than at small independents, so calling ahead is worthwhile.

Is telehealth a real option for Rezdiffra in Tennessee?

Yes, with a caveat. Tennessee permits practitioners to establish a prescriber-patient relationship through synchronous audio-video telehealth visits, provided the standard of care for diagnosis and monitoring is met. This is a genuine access route, not a workaround, and it matters in a state where specialty access is geographically uneven, many Tennessee counties are designated primary-care shortage areas by federal health workforce data, and gastroenterology and hepatology subspecialty access is generally scarcer still in rural areas. The exact current count of shortage-designated counties changes periodically and should be checked against the federal shortage-area database rather than quoted as a fixed figure.

The caveat: a telehealth visit does not substitute for fibrosis staging. Patients still need FibroScan results, a FIB-4 score, or biopsy pathology available before a telehealth prescriber can appropriately prescribe. And if using an out-of-state telehealth service, confirm the individual prescriber holds an active Tennessee license, a license in another state does not authorize prescribing to a patient located in Tennessee.

What labs come before the first dose

Lab work does two jobs: it establishes eligibility (fibrosis stage) and a safety baseline. Based on the FDA label and standard clinical practice for this drug class, expect:

• Fibrosis staging: FibroScan/CAP score, FIB-4 index, and biopsy if noninvasive results are indeterminate or a payer requires it
• Liver function panel: ALT, AST, GGT, alkaline phosphatase, total bilirubin, albumin
• Thyroid function: baseline TSH and free T4, because resmetirom acts on a thyroid hormone receptor pathway; the label calls for monitoring even though the drug was designed to be liver-selective
• Lipid panel: baseline LDL cholesterol and triglycerides, since resmetirom's effect on lipids is a documented secondary effect worth tracking
• Clinician's judgment: hepatitis B/C serologies to rule out viral causes, and hemoglobin A1c given the overlap between MASH and type 2 diabetes

Confirm the current, complete monitoring schedule against the FDA-approved label rather than this summary, since labeling can be updated.

Pharmacy channels in Tennessee: specialty, retail, and 503A compounding

Specialty pharmacy is the most common channel. These pharmacies typically coordinate prior authorization and copay assistance enrollment and ship to a patient's home.

Retail pharmacy dispensing is possible where a pharmacy stocks the drug; stock is inconsistent, particularly outside the state's larger metro areas.

503A compounding pharmacies, licensed by the Tennessee Board of Pharmacy, may compound resmetirom under a valid patient-specific prescription, consistent with federal Section 503A of the FD&C Act. A compounded preparation is not the FDA-approved commercial product; it has not gone through the same manufacturing review, and a prescriber should be involved in the decision to use one rather than the approved tablet. Compounded product generally cannot cross state lines unless the pharmacy also holds a nonresident pharmacy license in the receiving state.

Insurance and prior authorization: what varies, and by how much

Coverage differs sharply by payer category, and the details below should be treated as generally true patterns rather than guarantees for any specific plan.

Commercial insurance plans covering Tennessee residents generally place resmetirom on a specialty tier and require prior authorization. Typical documentation requested includes confirmed MASH diagnosis, fibrosis stage F2 or F3 (not F0/F1, and not F4/cirrhosis), evidence of attempted lifestyle modification, baseline labs, and a letter of medical necessity. If a request is denied, patients have appeal rights under Tennessee's insurance regulatory framework; the specific appeal process depends on the plan type (fully insured, self-funded, or Medicare Advantage) and should be confirmed with the insurer.

TennCare (Tennessee Medicaid): as of this writing, TennCare does not cover resmetirom for the MASH indication; TennCare pharmacy coverage does change, so confirm current formulary status directly with TennCare or the patient's managed care organization before assuming this is still accurate.

Medicare Part D: coverage depends on the individual plan's formulary. Resmetirom may be listed as a specialty tier drug requiring prior authorization on some plans and excluded on others. Check the specific plan's current formulary.

Cost and assistance: what to verify before quoting a number

Resmetirom is a specialty-tier drug with a list price in the tens of thousands of dollars annually. Because list prices, manufacturer copay program terms, and patient assistance program eligibility change and are not fixed by this article's source material, do not quote a specific dollar figure to a patient without checking the manufacturer's current program terms and the patient's specific plan. In general:

• Commercially insured patients may be eligible for manufacturer copay assistance, which typically excludes patients on Medicare, Medicaid, or other government insurance under anti-kickback rules.
• Uninsured patients may be eligible for a manufacturer patient assistance program based on income, subject to current program rules.
• Clinical trial enrollment (searchable through the federal clinical trials registry) is sometimes an access route with no drug cost, though eligibility and site availability change.

Who can prescribe it: MD, DO, NP, or PA

Tennessee does not add a state-specific restriction limiting resmetirom to a particular specialty:

• MDs and DOs have full, unrestricted prescriptive authority for FDA-approved medications.
• NPs with an active Tennessee APRN license can prescribe it independently under the state's current full-practice-authority framework.
• PAs prescribe under a collaborative agreement with a supervising physician; the agreement needs to cover the relevant drug class and specialty scope.

Most prescriptions in practice come from gastroenterology or hepatology because that specialty typically runs the fibrosis workup, but a primary care provider with the diagnostic results in hand is not legally barred from prescribing.

A realistic timeline

The elapsed time from first appointment to first dose depends heavily on how fibrosis staging is done and how quickly the payer processes prior authorization:

• Initial visit and lab orders: one visit, plus several days for results
• FibroScan or imaging: same-day in some offices, or a scheduling delay of one to a few weeks elsewhere
• Liver biopsy, if needed: typically adds several weeks including pathology turnaround
• Prior authorization: commonly takes one to three weeks for an initial determination, longer if appealed
• Pharmacy fulfillment after PA approval: typically under two weeks

A patient with FibroScan access and fast commercial-plan prior authorization may move from first visit to first dose in a few weeks. A patient who needs biopsy and whose PA is initially denied and appealed should expect a substantially longer timeline, potentially two to three months.

Transferring a prescription into Tennessee

Tennessee pharmacies can accept prescription transfers from out-of-state pharmacies under standard Board of Pharmacy transfer rules. For specialty pharmacy dispensing specifically, a transfer often triggers re-enrollment in the specialty pharmacy's program, and a new prior authorization is usually required if the patient's insurance plan changed with the move. If the insurance plan did not change, an existing PA may carry over, but this should be confirmed with both the pharmacy and the insurer rather than assumed. Patients using a telehealth prescriber should confirm that prescriber holds a Tennessee license, or establish care with a Tennessee-licensed prescriber before refills run out.

What is established, what is plausible, and what is not established

Established: Resmetirom is FDA-approved for MASH with F2-F3 fibrosis; Tennessee permits telehealth prescribing and 503A compounding under standard federal and state rules; prescriptive authority extends to MDs, DOs, NPs, and PAs practicing within their scope; most commercial payers require prior authorization for specialty-tier drugs like this one.

Plausible but not confirmed by the sources here: exact trial-level efficacy percentages, an exact current wholesale price, and an exact current count of Tennessee counties with specialist shortages, these numbers move and should be checked against a primary source (the FDA label, the published trial report, or the current HRSA shortage-area database) before being repeated as precise figures.

Not established: that resmetirom is appropriate for fibrosis stages outside F2-F3, that a compounded version is clinically equivalent to the FDA-approved tablet, and that any specific Tennessee insurer's current PA criteria match the general pattern described above. Basic research into fibrosis biology, including work on free-fatty-acid receptor pathways such as FFA1 and FFA4 in organ fibrosis more broadly, continues to explore mechanisms of fibrosis across organs, but that mechanistic research does not itself establish clinical guidance for resmetirom use and should not be read as trial-level evidence for this drug.

If a patient develops signs of liver decompensation (jaundice, confusion, marked abdominal swelling, or gastrointestinal bleeding) or a severe allergic reaction, that is an urgent care or emergency situation independent of anything in this article, and should not wait on a prior authorization decision.

Verification checklist before you rely on any specific fact in this article

Some facts about resmetirom access are stable and unlikely to change soon. Others are tied to a payer, a state program, or a price, and can change without notice. Before using this article to counsel a patient, sort the claim you're relying on into one of these two buckets and verify accordingly.

Stable, federal or clinical (verify occasionally, source = FDA/clinical literature):

• FDA approval status and the F2-F3 fibrosis indication, check the current FDA label
• Weight-based dosing structure, check the current FDA label
• Recommended baseline monitoring categories (liver panel, thyroid function, lipids), check the current FDA label
• Tennessee's general scope-of-practice rules for MDs, DOs, NPs, and PAs, check the Tennessee Board of Medical Examiners and Board of Nursing
• Federal 503A compounding framework, check FDA's 503A guidance

Date-sensitive, payer or state-specific (verify before every patient conversation, source = the specific plan, pharmacy, or program):

• Whether TennCare covers resmetirom for MASH
• Any specific commercial insurer's current prior-authorization criteria and turnaround time
• Medicare Part D formulary status for a given plan
• Manufacturer copay assistance program terms and income thresholds for patient assistance
• Current wholesale acquisition cost or cash price
• Which specific Tennessee retail or specialty pharmacies currently stock the drug
• Current count of HRSA-designated shortage counties in Tennessee
• Active clinical trial sites and enrollment status

If a fact falls in the second bucket, do not repeat a number from memory or from an older article. Confirm it the same day you use it.